Commentary on: Arpe total joint arthroplasty for trapeziometacarpal osteoarthritis: 80 thumbs in 63 patients with a minimum of 10 years follow-up

Trapezial dysplasia and concomitant disorders around the thumb can influence the outcome after total carpometacarpal joint replacement: Report of two cases, short review of literature, and update to the Arpe™ prosthesis

“…The third major procedure is the CMCJ I arthrodesis, however, due to its high complication rate it is not recommended for women aged 40 years and older, and the patient's satisfaction is only high in 88 % of cases when osseous fusion is obtained [57][58][59]. Four long-term outcome studies with the Arpe prosthesis revealed a remarkable survivorship after 10 to 12 years with relative portions ranging from 85% to 93.3% associated with a high patient satisfaction (Figure 7A-B), and after 15 years with 80% that is not far from the 15year total hip survival reported from the combined Nordic Arthroplasty Registry Association in 2014 and it can be considered acceptable [60][61][62][63][64]. Despite these good and reliable results, the Arpe prosthesis was surprisingly withdrawn from the markektplace by the company in 2021 in the absence of any scientific evidence for it, and this is the same inexplicable situation such as with the Lateral Resurfacing Elbow system and the Maestro wrist prosthesis by the same company [65,66].…”